John Heymach, MD, PhD

Articles

NSCLC: Immunotherapy in Patients With Concomitant KRAS/TP53 Mutations

June 27th 2022

Expert oncologist John Heymach, MD, PhD, addresses the potential role of immunotherapy in concomitant KRAS/TP53-mutated NSCLC.

I/O Therapy in KRAS-Mutant NSCLC With Concomitant STK11 or KEAP1 Mutations

June 27th 2022

Insight on the potential role of immunotherapy in patients with NSCLC and concomitant KRAS/STK11 or KRAS/KEAP1 mutations.

Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?

June 20th 2022

John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements.

Overcoming Barriers to Molecular Profiling in NSCLC Management

June 20th 2022

Expert perspectives on the prevalence of molecular profiling in NSCLC, and the unmet needs and barriers preventing the uptake of routine molecular testing.

NSCLC: The Role of Liquid Biopsy in Molecular Testing and Treatment Decision-Making

June 13th 2022

A brief discussion on insufficient tissue results in molecular profiling for NSCLC and how this can be avoided or addressed via liquid biopsy.

Testing Strategies for Actionable Mutations in Non–Small Cell Lung Cancer

June 13th 2022

Expert oncologist John Heymach, MD, PhD, provides comprehensive insight on testing strategies for actionable mutations in NSCLC.

Dr. Heymach on the Future of Immunotherapy in NSCLC

March 31st 2021

John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.

Dr. Heymach on New KRAS Subsets in Lung Cancer

April 19th 2015

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.